Style Claims Must Be Supported by an Adequate Written Description U.S. patent claims have a preamble, and, in most cases, the ...

William Blair initiated coverage of Xencor (XNCR) with an Outperform rating. The firm believes the biopharmaceutical industry is entering a ...

Conference call with management will be held on April 16 at 2 pm hosted by JPMorgan. Webcast LinkStay Ahead of the Market: Discover ...

This irresponsible form of political theater is on display regarding the necessary and critical role capital investing plays ...

Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline ...

Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Current written description jurisprudence can make it difficult to obtain broad antibody patents, leading practitioners to explore ...

American Century Companies Inc. raised its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 11.1% during the ...

PASADENA, Calif., March 13, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today ...